• News
  • World
  • Economy
  • Society
  • Health
  • Sport
  • Culture
  • Techno
  • Science
The Gal Times
No Result
View All Result
No Result
View All Result
The Gal Times
No Result
View All Result

COVID-19: How will we know that vaccines work and are safe?

Nick Quaz by Nick Quaz
November 16, 2020
in Science
0
COVID-19: How will we know that vaccines work and are safe?


16.11.2020
01:41

It is not easy to determine its effectiveness. First, researchers need to know if simply giving someone an injection is helpful. Large numbers of people participate in medical trials, half of whom receive it and the other half a placebo

By Adam Kleczkowski November 16, 2020 Share on FacebookShare Share on TwitterTweet Share on WhatsAppShare

COVID-19: How will we know that vaccines work and are safe?

PHOTO FILE: A woman holds a small vial labeled “COVID-19 Vaccine” and a medical syringe in this illustration taken on April 10, 2020. REUTERS / Dado Ruvic

RelatedPosts

Archaeologist Rainer Kune discovered biblical city in Spain using satellite photos

Archaeologist Rainer Kune discovered biblical city in Spain using satellite photos

January 2, 2021

Science and its unexpected role in 2020 (and how to take advantage of this opportunity in Peru)

December 26, 2020
Santrich does not appear among those indicted in the case of drug trafficking and money laundering in the 2019 archive

Santrich does not appear among those indicted in the case of drug trafficking and money laundering in the 2019 archive

November 16, 2020

Pfizer and BioNTech have just released the interim results of the trial of their vaccine against the COVID-19 disease. Although it is not the only one in the final stages of testing, the sheer scale of its trial and its extremely careful design, not to mention its promising results, have generated more than understandable excitement around the world. Now that we are getting closer and closer to the long-awaited start of vaccination, it is worth learning how statistics help physicians establish vaccine safety.

How effective are vaccines?

It is not easy to determine the efficacy of a vaccine. First, researchers need to know if simply giving someone an injection is helpful. Large numbers of people participate in medical trials, half of whom receive the vaccine and the other half a placebo. The participants then have to expose themselves to infection, with the expectation that most of the patients in the control group will become ill, but that the vaccine will protect at least some of the treated group.

In certain situations, as with HIV or Ebola, even the fact of administering a placebo is ethically very controversial, since we are talking about a very high mortality rate in these cases. In the coronavirus disease, scientists are forced to rely on natural infection, since, to date, there are no studies that intentionally expose participants to the coronavirus. As a result, the vaccine efficacy estimate is based on the relatively small number of people who contracted COVID-19 from contact with other infected people.

The efficacy of the vaccine reflects the percentage of the number of people who fell ill within the group who had been vaccinated and the group who had not received the vaccine. The Pfizer / BioNTech trial had nearly 44,000 participants, of whom 21,999 received the vaccine.

Researchers use statistical analysis to mark milestones where they can be increasingly confident that the vaccine works, or not, as dropper cases emerge. If the number of participants were small, it would not be clear whether the differences between the placebo group and the treated group would be real or just a product of chance.

Statisticians resort to the so-called study of statistical power to find out how many cases we need to observe. For the Pfizer and BioNTech vaccine, it was determined that testing would continue until a total of 164 cases were recorded, all based on the assumption that the vaccine would be 60% effective. For this calculation, the efficacy of the seasonal influenza vaccine was taken as a reference. However, and given that the figures exceeded expectations, the laboratory decided to publish the results that were already available in one of the intermediate analysis points.

94 cases were reported, and the division of the approximately 86 cases in the placebo group and the 8 cases among the vaccinated patients yielded an efficacy of 90%. Thus, we would be facing a level of protection against the virus more than remarkable. Even though the study is conducted from a relatively small number of cases, the statistical analysis allows the researchers to extrapolate the results to what might happen once the vaccine is on the market.

People of different ages and ethnic groups participated in the trial, but more studies are still needed to assess whether vaccination would protect the most vulnerable groups.

The ultimate efficacy may be lower, as administering the treatment is complex for many logistical reasons, including the fact that messenger RNA vaccines, such as Pfizer's, must be stored at very low temperatures. In the real world, the vaccine could not be kept at the proper temperature and could therefore go bad.

ADVERTISEMENT

How safe is the vaccine?

In the event that the vaccine was administered widely, both the medical community and society as a whole could be reassured about its safety.

The Pfizer vaccine was administered to 21,999 people. Some transmitted a reaction similar to that experienced after getting vaccinated against seasonal flu. So far, no serious side effects have been reported. However, how can we be certain that this will continue to be the case when the drug reaches millions of people?

To do this, statisticians developed the rule of three. According to this rule, if 21,999 participants were vaccinated and did not have any side effects, that is, a safety of 95% was demonstrated, it is expected that the chances of the vaccine having side effects will be below three ( hence the name) divided by 21,999 and will therefore be less than 1 in 10,000. The chances of side effects appearing even lower, but the researchers prefer to go further in the trial to confirm this.

Safety is as important as efficacy. If we keep the probability of 1 in 10,000 and move it to the 300 million people who are expected to be vaccinated in the United States alone, the number of people who would suffer the side effects would rise to 30,000, a high number. It is clear that doctors have to ensure that they will not cause harm, and that any serious side effect attributable to the vaccine would greatly damage their prestige and significantly affect their uptake.

How should the vaccine be used to be effective and safe?

Health authorities are now working on how to incorporate vaccination into their national programs, but the details depend on different factors. The UK Government has already purchased 40 million doses of the Pfizer vaccine, which, taking into account that it is administered in two doses, would vaccinate 20 million people, that is, the entire 55-year-old population onwards. However, vaccination will not be quick, as both production and distribution of vaccines will take time.

COVID-19: How will we know that vaccines work and are safe?

The UK government has commissioned 40 million doses of the Pfizer vaccine. (Alberto Pezzali / Pool via REUTERS)

The strategy also depends on what the vaccination program aims to achieve. Children's vaccines, such as measles, are given to newborns to maintain herd immunity. In this case, we are talking about the fact that only a relatively small percentage of the population needs to be vaccinated. Given the rapid spread of COVID-19 and the extremely high levels of infection, the vaccine should reach a much larger number of people.

Predictions regarding the level of immunity required to achieve herd immunity depend on our calculation of the COVID-19 basic reproductive number, R₀. In the absence of any other control measure, this value is around 3, so at least 67% of the population would need to be totally immune to stop the epidemic from growing. If the goal were to eradicate the virus, even higher values would have to be achieved.

This level is hardly achievable with an efficacy of 60%, even when it is decided to vaccinate the entire population. The R₀ = 3 value assumes a return to pre-pandemic behavior. If we maintained a certain level of restrictions and continued to use masks, R₀ could be lower and group immunity would become easier to achieve.

Among the positives, it should be noted that our simple models may be being too pessimistic about levels to talk about group immunity. Furthermore, if it turns out that around 20% of the population would have already contracted COVID-19, the level of vaccination required could be infinitely more affordable.

Another option would be to administer the vaccine to segments of the population that have a high risk of infection (health workers and caregivers) or that present a high risk of death (vulnerable people, patients in nursing homes). In fact, this is precisely the recommended strategy in the UK.

Are we close to winning the battle against the virus?

The results of the Pfizer vaccine trial are very promising. But the truth is that the road to eradicating the coronavirus can be long and difficult. In addition to establishing the potential of the vaccine to protect us against the virus, we must know if it provides us with permanent immunity or if it must be administered repeatedly, as is the case with vaccines against tetanus or seasonal flu.

Policymakers and researchers must also balance what is needed to curb the pandemic and fears of side effects along with doubts about the vaccine. While these concerns can be easy to dismiss, they must be taken seriously if vaccination is to be successful.

Adam Kleczkowski is Professor of Mathematics and Statistics at the University of Strathclyde (Scotland)

Article originally published on The Conversation

Source

Share Button

Related Posts

Archaeologist Rainer Kune discovered biblical city in Spain using satellite photos

Archaeologist Rainer Kune discovered biblical city in Spain using satellite photos

by Nick Quaz
January 2, 2021
0

German archaeologist Rainer Kune discovered an ancient city from biblical times in Spain. He studied satellite photos of a reserve...

Science and its unexpected role in 2020 (and how to take advantage of this opportunity in Peru)

by Nick Quaz
December 26, 2020
0

Less than a year after the start of the COVID-19 pandemic , there are already approved emergency vaccines and several...

Santrich does not appear among those indicted in the case of drug trafficking and money laundering in the 2019 archive

Santrich does not appear among those indicted in the case of drug trafficking and money laundering in the 2019 archive

by Nick Quaz
November 16, 2020
0

16.11.2020 10:08 Despite the fact that his name came up in the case of Iván Márquez's nephew for Drug Trafficking,...

What's the Big Difference Between Pfizer and Moderna COVID-19 Vaccines

What's the Big Difference Between Pfizer and Moderna COVID-19 Vaccines

by Nick Quaz
November 16, 2020
0

16.11.2020 10:08 The two American laboratories reported an efficiency of over 90% and are developed with the same technology, but...

The Moderna laboratory reported that its vaccine against COVID-19 has an efficacy of 94.5 percent

The Moderna laboratory reported that its vaccine against COVID-19 has an efficacy of 94.5 percent

by Nick Quaz
November 16, 2020
0

16.11.2020 08:08 The formula of the American pharmaceutical company also requires to be frozen, like that of Pfizer, but it...

A study says that COVID-19 was already circulating in Italy in September 2019, long before China recognized the existence of the virus

A study says that COVID-19 was already circulating in Italy in September 2019, long before China recognized the existence of the virus

by Nick Quaz
November 16, 2020
0

16.11.2020 07:08 Scientists from the National Cancer Institute in Milan pointed out that antibodies to the virus were already in...

Fifteen viruses that have changed the history of mankind

Fifteen viruses that have changed the history of mankind

by Nick Quaz
November 16, 2020
0

16.11.2020 01:40 Pandemics, once they end, change some of our ways of relating to each other and introduce new customs...

Common Mutation May Make COVID-19 More Vulnerable to Vaccine, Study Warns

Common Mutation May Make COVID-19 More Vulnerable to Vaccine, Study Warns

by Nick Quaz
November 15, 2020
0

15.11.2020 23:08 While the mutated strain spreads faster, it is slightly more sensitive to drug neutralization of antibodies, said researchers...

NASA and SpaceX successfully launched historic manned mission to the International Space Station

NASA and SpaceX successfully launched historic manned mission to the International Space Station

by Nick Quaz
November 15, 2020
0

15.11.2020 21:08 A SpaceX Falcon 9 rocket with the Dragon capsule on top took off from Cape Canaveral, Florida November...

Hunting for the origins of COVID-19: WHO's challenges to unravel the mystery of the root of the pandemic

Hunting for the origins of COVID-19: WHO's challenges to unravel the mystery of the root of the pandemic

by Nick Quaz
November 15, 2020
0

15.11.2020 13:08 Tracing the virus's path is important to prevent future viral spills, but scientists say the World Health Organization...

No Result
View All Result

Recommended

  • In China, the coronavirus vaccine have shown positive results
  • Efficacy vs effectiveness of a vaccine: how they are measured and how they differ
  • Why a 66% effective vaccine is great news
  • The extraordinary request from Axel Kisilov to Horacio Rodriguez Larita
  • 4 Pfizer vaccines were administered and hospitalized for possible overdose
  • The study confirms how long immunity lasts after infection with the virus
  • The European Medicines Agency revealed that it expects to approve a first coronavirus vaccine before the end of the year
  • WHO urges rich countries to end deals with pharmaceutical companies for the COVID-19 vaccine.
  • The European regulator concluded that Pfizer and BioNTech vaccines were not associated with deaths after application
  • Novavax’s COVID-19 vaccine showed 89% effectiveness in a large-scale study

Recent News

  • Crossing between Gioja and Randazzo | Sudden comeback …
  • The advice La Coca Sarli gave Florencia Peña not to reduce her bust
  • OPEC and its allies have agreed to keep the cuts in oil production: a new hike in the price of a barrel
  • Enzo’s Big Million’s Poet and the Definition of Alvarez
  • They found a hidden layer in the center of the Earth that would reveal an exciting event
  • Market size and share of traditional Chinese medicines in 2021 by industry impact, sales revenue, future orders, growth factors and drivers, emerging trends, competitive landscape and outlook to 2026
  • A 1.5 billion peso stadium, packed with VIP boxes and cutting edge technology, in the second poorest province in Argentina.
Facebook Twitter

Categories

  • Culture
  • Economy
  • Health
  • News
  • Science
  • Society
  • Sport
  • Techno
  • World

© 2021 JNews - Premium WordPress news & magazine theme by Jegtheme.

No Result
View All Result
  • Contact us
  • Privacy Policy

© 2021 JNews - Premium WordPress news & magazine theme by Jegtheme.